ximelagatran

(redirected from Melagatran)

ximelagatran

An oral direct thrombin inhibitor drug used as an anticoagulant alternative to warfarin in the management of thromboembolism. In late 2004 the American FDA rejected an application for approval of this drug on the grounds of liver toxicity.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Preusch et al., "Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
showed that the use of anticoagulants such as melagatran could significantly reduce IBMIR in vitro in a blood loop model [50].
Nilsson, "Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor Melagatran in clinical islet transplantation," Diabetes, vol.
Effect of phenprocoumon on monitoring ot lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method.
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Patients in the ximelagatran group received a 2-mg dose of the injected form of the drug, melagatran, immediately before surgery and a 3-mg dose of subcutaneous melagatran during the evening after their surgery.
Melagatran is currently under investigation in clinical trials (11-14).
Here we describe the additive and synergistic actions of the DTIs lepirudin, argatroban, and melagatran on the effects of the oral anticoagulant phenprocoumon on PT.
SPORTIF (Stroke Prevention using an Oral Direct Thrombin Inhibitor in Atrial Fibrillation) II-III-IV calismalari, METHRO (Melagatran For Thrombin Inhibition In Orthopaedic Surgery) I-II calismalari ve THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events) III calismasinin sonuclari ozet olarak okuyucuya aktarilmaktadir.
Ximelagatran emilimi ve melagatran olusumu etnik gruplar arasinda farklilik gostermez.
Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers, following intravenous, subcutaneous and oral administration.